EP1189624A4 - Hla-bindende peptide und deren verwendung - Google Patents

Hla-bindende peptide und deren verwendung

Info

Publication number
EP1189624A4
EP1189624A4 EP00944976A EP00944976A EP1189624A4 EP 1189624 A4 EP1189624 A4 EP 1189624A4 EP 00944976 A EP00944976 A EP 00944976A EP 00944976 A EP00944976 A EP 00944976A EP 1189624 A4 EP1189624 A4 EP 1189624A4
Authority
EP
European Patent Office
Prior art keywords
hla
peptides
binding peptides
immunogenic
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00944976A
Other languages
English (en)
French (fr)
Other versions
EP1189624A1 (de
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Priority to EP07117445A priority Critical patent/EP1917970B1/de
Publication of EP1189624A1 publication Critical patent/EP1189624A1/de
Publication of EP1189624A4 publication Critical patent/EP1189624A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP00944976A 1999-06-29 2000-06-28 Hla-bindende peptide und deren verwendung Withdrawn EP1189624A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07117445A EP1917970B1 (de) 1999-06-29 2000-06-28 Hla-bindende Peptide und ihre Verwendungen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14142299P 1999-06-29 1999-06-29
US141422P 1999-06-29
PCT/US2000/017842 WO2001000225A1 (en) 1999-06-29 2000-06-28 Hla binding peptides and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07117445A Division EP1917970B1 (de) 1999-06-29 2000-06-28 Hla-bindende Peptide und ihre Verwendungen

Publications (2)

Publication Number Publication Date
EP1189624A1 EP1189624A1 (de) 2002-03-27
EP1189624A4 true EP1189624A4 (de) 2005-02-23

Family

ID=22495620

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00944976A Withdrawn EP1189624A4 (de) 1999-06-29 2000-06-28 Hla-bindende peptide und deren verwendung
EP07117445A Expired - Lifetime EP1917970B1 (de) 1999-06-29 2000-06-28 Hla-bindende Peptide und ihre Verwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP07117445A Expired - Lifetime EP1917970B1 (de) 1999-06-29 2000-06-28 Hla-bindende Peptide und ihre Verwendungen

Country Status (6)

Country Link
EP (2) EP1189624A4 (de)
JP (1) JP2003535024A (de)
AT (1) ATE512666T1 (de)
AU (1) AU5898400A (de)
CA (1) CA2370413A1 (de)
WO (1) WO2001000225A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20040096445A1 (en) * 1999-06-30 2004-05-20 John Sidney Subunit vaccines with A2 supermotifs
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
JP2003509465A (ja) * 1999-07-19 2003-03-11 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
EP2177534A3 (de) 1999-11-18 2010-07-14 Pharmexa Inc. Heteroklitische Analoga von Klasse-i Epitopen
EP1568373A3 (de) * 1999-12-10 2005-12-21 Epimmune Inc. Induzierung von zellulärer Immunantwort auf HER2/neu mit Hilfe von Peptid- und Nukleinsäurezubereitungen
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
WO2001074847A2 (en) * 2000-03-30 2001-10-11 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
DK1292321T3 (da) * 2000-05-12 2012-01-30 Northwest Biotherapeutics Inc Fremgangsmåde til at forøge klasse 1 præsentation af exogene antigener gennem humane dendritiske celler
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
SI1620456T1 (sl) * 2003-04-18 2014-05-30 Biotech Synergy, Inc. Hla-a2 s tumorjem povezan antigen peptidov in sestavki
TWI262192B (en) * 2003-07-01 2006-09-21 Univ Nat Taiwan Labeling peptide for nasopharyngeal carcinoma (NPC) cells
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
JP2007277092A (ja) * 2004-06-17 2007-10-25 Univ Kurume 前立腺関連抗原由来ｈｌａ−ａ２結合性ペプチド
EP1840133A1 (de) * 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. Neue immunomodulierende Oligopeptide
EP2023952B1 (de) 2006-05-18 2015-07-15 Epimmune Inc. Induktion von immunreaktionen auf das influenzavirus mithilfe von polypepitd- und nukleinsäure-zusammensetzungen
US8282938B2 (en) 2008-11-28 2012-10-09 National Institute Of Infectious Diseases Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
US9115402B2 (en) * 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
WO2015130488A2 (en) 2014-02-28 2015-09-03 Immunotope, Inc. Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (de) 2014-12-19 2020-11-25 The Broad Institute, Inc. Verfahren zum profiling vom t-zell-rezeptor-repertoire
JP6913032B2 (ja) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
US11712465B2 (en) 2016-10-07 2023-08-01 Enterome S.A. Microbiota sequence variants of tumor-related antigenic epitopes
IL296165B2 (en) * 2016-10-07 2023-10-01 Enterome S A Immunogenic compounds for cancer treatment
CN117801069A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
BR112019013402A2 (pt) 2016-12-28 2020-03-03 Invvax, Inc. Vacinas de influenza
EP3574116A1 (de) 2017-01-24 2019-12-04 The Broad Institute, Inc. Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
EP3606550A2 (de) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Proteinantigene und verwendungen davon
NL2019814B1 (en) * 2017-10-26 2019-05-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Methods for producing a MHC multimer.
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
ES2935702T3 (es) 2018-04-11 2023-03-09 Enterome S A Péptidos antigénicos para la prevención y el tratamiento del cáncer
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1995003777A1 (en) * 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509677A (ja) * 1997-01-31 2001-07-24 エピミューン，インコーポレイティド Ｃｔｌを活性化するためのペプチドおよびペプチド担持抗原提示細胞
JP2003524016A (ja) * 2000-02-23 2003-08-12 エピミューン， インコーポレイテッド Ｈｌａ結合ペプチドおよびそれらの用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1995003777A1 (en) * 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUERCIO DEL M-F ET AL: "BINDING OF A PEPTIDE ANTIGEN TO MULTIPLE HLA ALLELES ALLOWS DEFINITION OF AN A2-LIKE SUPERTYPE", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 154, 1995, pages 685 - 693, XP002055570, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
EP1917970A2 (de) 2008-05-07
CA2370413A1 (en) 2001-01-04
JP2003535024A (ja) 2003-11-25
EP1917970B1 (de) 2011-06-15
EP1917970A3 (de) 2008-09-24
WO2001000225A1 (en) 2001-01-04
ATE512666T1 (de) 2011-07-15
AU5898400A (en) 2001-01-31
EP1189624A1 (de) 2002-03-27

Similar Documents

Publication Publication Date Title
ATE512666T1 (de) Hla-bindende peptide und ihre verwendungen
ATE536187T1 (de) Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
ATE296313T1 (de) Hla-a2.1 bindende peptide und deren verwendung
BR9406652A (pt) Composição
ATE342730T1 (de) Hla bindepeptide und ihre verwendungen
DK0941478T4 (da) Assaymetode for peptidspecifikke T-celler
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
ATE454159T1 (de) Von survivin abgeleitete peptide und deren verwendung
DE60142689D1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
ATE429247T1 (de) Hla-bindende peptide und ihre verwendungen
WO2004007528A3 (en) Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange
DE60045776D1 (de) Hla-bindungspeptide und ihre anwendungszwecke
ATE336579T1 (de) Isolierte mhc-klasse ii-bindende peptide, und deren verwendung
ATE399176T1 (de) Nonapeptidische ny-eso-1 derivate und deren verwendung
ES1037474U (es) Marquesina para paradas de autobuses, tranvias y similares.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050111

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071220